Rezultaty - Somnath Sarkar
- Rezultaty 1 - 8 Rezultaty od 8
-
1
Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials od Fairooz F. Kabbinavar, Herbert I. Hurwitz, Jing Yi, Somnath Sarkar, Oliver Rosen
Wydane 2008Artigo -
2
-
3
Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer od Fairooz F. Kabbinavar, Julie Hambleton, R. Mass, Herbert I. Hurwitz, Emily K. Bergsland, Somnath Sarkar
Wydane 2005Artigo -
4
-
5
Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study od Olof Johnell, John А. Kanis, Dennis M. Black, Á. Balogh, Gyula Poór, Somnath Sarkar, Chunmei Zhou, Imre Pávó
Wydane 2004Artigo -
6
Contribution of Raloxifene and Calcium and Vitamin D<sub>3</sub>Supplementation to the Increase of the Degree of Mineralization of Bone in Postmenopausal Women od G. Boivin, Paul Lips, Susan M. Ott, Kristine D. Harper, Somnath Sarkar, Karen V. Pinette, Pierre J. Meunier
Wydane 2003Artigo -
7
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107 od Axel Grothey, Eric Hedrick, R. Mass, Somnath Sarkar, Sam Suzuki, Ramesh K. Ramanathan, Herbert I. Hurwitz, Richard M. Goldberg, Daniel J. Sargent
Wydane 2008Artigo -
8
Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial od Pierre D. Delmas, Kristine E. Ensrud, Jonathan D. Adachi, Kristine D. Harper, Somnath Sarkar, C. Gennari, Jean‐Yves Reginster, Huibert A. P. Pols, Robert R. Recker, Steven T. Harris, Wentao Wu, Harry K. Genant, Dennis M. Black, Richard Eastell
Wydane 2002Artigo
Narzędzie wyszukiwania:
Podobne hasła
Cancer
Internal medicine
Medicine
Surgery
Breast cancer
Osteoporosis
Raloxifene
Alternative medicine
Confidence interval
Estrogen receptor
Pathology
Placebo
Bevacizumab
Bone mineral
Chemotherapy
Colorectal cancer
Fluorouracil
Hazard ratio
Oncology
Urology
Cohort
Femoral neck
Irinotecan
Progression-free survival
Randomized controlled trial
Adverse effect
Bone density
Bone remodeling
Cumulative incidence
Dentistry